Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × Nerve Growth Factor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

pembrolizumab 99 Cyclophosphamide 73 Carboplatin 57 Injections 54 fludarabine 52 Bevacizumab 46 Gemcitabine 38 Nivolumab 36 venetoclax 35 Paclitaxel 35 Cisplatin 35 Dexamethasone 34 Specimen Handling 33 Docetaxel 32 Magnetic Resonance Spectroscopy 31 Biopsy 29 Temozolomide 25 atezolizumab 24 Pemetrexed 23 Irinotecan 23 toripalimab 22 Azacitidine 22 Oxaliplatin 21 Fluorouracil 21 Capecitabine 21 abemaciclib 20 Rituximab 20 Fulvestrant 20 Radiotherapy 19 Cetuximab 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07008703 2025-06-06

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1/2 Recruiting

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡